Research Article Details
| Article ID: | A26851 |
| PMID: | 19652102 |
| Source: | Arch Pediatr Adolesc Med |
| Title: | Onset of puberty and cardiovascular risk factors in untreated obese children and adolescents: a 1-year follow-up study. |
| Abstract: | OBJECTIVE: To determine the course of obesity-associated nonalcoholic fatty liver disease (NAFLD) and the cardiovascular risk factors of hypertension, dyslipidemia, and disturbed glucose metabolism in untreated obese children. DESIGN: Obese children were examined prospectively at baseline and 1 year later. SETTING: Obesity clinic. PARTICIPANTS: A total of 287 untreated obese children; 53.3% were girls, the mean age was 11.4 years, and the mean body mass index (calculated as weight in kilograms divided by height in meters squared) was 28.2. MAIN OUTCOME MEASURES: Homeostasis model assessment of insulin resistance (HOMA-IR) values and prevalence of hypertension, dyslipidemia, impaired fasting glucose level, and NAFLD. RESULTS: At baseline, 20.6% of obese children had hypertension, 22.3% had dyslipidemia, 4.9% had impaired fasting glucose levels, and 29.3% had NAFLD. These prevalences, as well as weight status, remained stable at the 1-year follow-up visit. Increases (SDs) in prevalence of hypertension (16.1% [51.8%]), hypertriglyceridemia (9.7% [59.3%]), and impaired fasting glucose level (8.1% [32.9%]), as well as mean HOMA-IR value (0.42 [1.22]), were observed in 62 children entering puberty. In contrast, mean decreases (SDs) in hypertension (-18.8% [53.2%]), hypertriglyceridemia (-12.5% [53.1%]), impaired fasting glucose level (-6.3% [38.1%]), and NAFLD prevalence (-18.8% [44.5%]), as well as mean HOMA-IR value (-0.83 [2.56]), were observed in 50 children entering late puberty (P < .01 for change of pubertal status in the multivariate model). Changes in HOMA-IR values were only weakly related to changes in prevalence of cardiovascular risk factors or transaminase levels (r < 0.2). CONCLUSIONS: Cardiovascular risk factors worsened at onset of puberty and improved in late puberty in obese children whose weight status did not change. The weak correlation between HOMA-IR value and cardiovascular risk factors suggests that other characteristics may affect these disorders. |
| DOI: | 10.1001/archpediatrics.2009.123 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I12 | 10763 | Hypertension | An artery disease characterized by chronic elevated blood pressure in the arteries. https://en.wikipedia.org/wiki/Hypertension, https://www.ncbi.nlm.nih.gov/pubmed/24352797 | disease of anatomical entity/ cardiovascular system disease/vascular disease/ artery disease | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |